IMiDs (Immunomodulatory drugs) and Multiple Myeloma
|
|
- Beatrice Austin
- 5 years ago
- Views:
Transcription
1 IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France
2 Disclosure of Conflict of Interest (List) Celgene Lecture fees, board, other honorarium Janssen Lecture fees, board Millenium/Takeda Lecture fees, board Onyx/Amgen Lecture fees, board LeoPharma Lecture fees, board Novartis Lecture fees
3 Patients (%) Approval of Novel Agents has Improved OS 1 Overall Survival from Time of Diagnosis Diagnosis Period Median OS months ,a 45 months p value p < a months months p = Time (months) Sustained improvement in OS seen over the diagnosis period Improvement in OS over this period attributed to use of novel agents and ASCT a Approval of Bort-, Thal-, and Len-containing regimens occurred during this time. 1. Kumar SK, et al. Blood. 28;111: Kumar SK, et al. Leukemia. 213.
4 Proportion Surviving Proportion Surviving Continued Improvement in OS in Novel-Agent Era There are 138 patients grouped into and cohorts Use of novel agents in treatment regimens improved OS Received Novel agents No Novel agents Follow up from diagnosis (years) Follow up from diagnosis (years) Survival p Median OS, years year estimated OS, % 4 51 <.1 Kumar SK, et al. Leukemia. 213.
5 Approval Timelines (EU) for Novel Therapies 28 June 213 Approved for RRMM 2 April 25 Bort (IV) as monotherapy for RRMM patients who received 1 prior treatment and who have undergone or are ineligible for BMT Approved for NDMM 29 August 28 Bort (IV) in combination with MP approved for NDMM patients ineligible for HDT with BMT 2 September 212 Bort (SC) as monotherapy for RRMM patients who received 1 prior treatment and who have undergone or are ineligible for BMT Bort in combination with TD approved for SCT-eligible NDMM patients April 24 Bort (IV) approved for RRMM patients who failed to respond to 2 prior treatment 14 June 27 Len in combination with DEX in RRMM patients who received 1 prior treatment a EMA approval dates can only be verified from 24 to the present. BMT, bone marrow transplant; EMA, European Medicines Agency; EU, European Union; IV, intravenous; SC, subcutaneous. 16 April 28 Thal in combination with MP in NDMM patients aged 65 years or ineligible for HDT 5 August 213 Pom + LoDex in relapsed and refractory patients with 2 prior regimens including Len and Bort EMA.
6 IMiDs (Immunomodulatory drugs)
7 IMiDs share a Phtaloyl ring Pthaloyl ring O N O H N O Glutarimide ring Lenalidomide O Thalidomide O N O H N O Additional amino group N H 2 Carbonyl removed Additional amino group Pomalidomide
8 IMiDs share mechanism of action: Overview Anti-myeloma Tumour suppressor gene upregulation and oncogene inhibition 1 4 Induction of cell-cycle arrest and apoptosis 1 5 Effects in drug-sensitive and drug-resistant cells 1 5 Stromal inhibition Inhibition of osteoclast differentiation 6,7 Inhibition of growth factor production 8 Inhibition of angiogenesis 9 IMiDs: Pomalidomide Immunomodulatory Enhanced immune function 8,1 14 Increased NK-mediated MM lysis 14,15 MM, multiple myeloma; NK, natural killer.
9 Molecular Structure of IMiDs (Immunomodulatory drugs)
10 Antitumor Activity of Thalidomide in Refractory Multiple Myeloma Seema Singhal, et al 1999;341:1565
11 SYSTEMATIC REVIEW OF PHASE II TRIALS OF THALIDOMIDE MONOTHERAPY IN RELAPSED MM Glasmacher A, Br J Haematol communications (24 full papers) patients - median dose > 2 mg/d in 86% of cases CR or VGPR (> 9%) 1.6 PR (>5%) % MR Survival data 1 year EFS 35 %, median EFS : 3 to 16 months 1 year SV 6 %, median SV : 14 months
12
13 Proportion of patients Proportion of patients MP versus MPT and MP versus MEL1 in newly diagnosed elderly MM patients: response* 1..8 Overall survival MP MPT MEL Progression-free survival MP MPT MEL Time from randomization (months) Time from randomization (months) Treatment PFS, months p value OS, months p value MP (n = 196) 17.8 ± ± 5.8 <.1.1 MPT (n = 125) 27.5 ± ± MEL1 (n = 126) 19.4 ± ± 2.7 * Median follow-up time: 51.5 months (IQR ). Facon T, et al. Lancet. 27;37:
14 MPT vs MP for previously untreated elderly patients with MM: Meta-analysis of 1685 individual-patient data from 6 randomized trials Survival proportion PFS HR=.67 in favor of MPT, p<.1 Median 14.9 mos ( ) Median 2.3 mos ( ) MPT MP months OS HR=.83 in favor of MPT, p=.5* Median 39.3 mos ( ) Median 32.7 mos ( ) MPT MP months *Cox model for treatment, with analysis stratified by study using a random effects (frailty) model Fayers et al. Blood 211;118:
15 Phase III trial of Thal + Dex compared with Dex alone in NDMM (MM-3) Multi-centre phase III study 47 patients with untreated symptomatic MM R A N D O M I Z A T I O N Thal/Dex (n = 235) Thalidomide: 5 mg/day escalating to 1 mg/day on day 15, and to 2 mg/day from day 1 of cycle 2 + dexamethasone: 4 mg on days 1 4, 9 12, and 17 2 (cycles 1 4), and days 1 4 (cycle 5 + ) Placebo/Dex (n = 235) Placebo: as for thalidomide above + dexamethasone: as for above 28-day cycles repeated until disease progression or unacceptable toxicity Stratification according to age, ECOG performance status, and 2 -microglobulin Primary end-point TTP ECOG = Eastern Cooperative Oncology Group; NDMM = newly diagnosed MM. Data from Rajkumar SV, et al. J Clin Oncol. 28;26:
16 Proportion of subjects with no progression Thal + Dex vs Dex in newly diagnosed MM (MM-3): TTP and overall survival Proportion of subjects surviving Time to progression (TTP) HR (95% CI):.43 (.32.58) Thal + Dex Placebo + Dex Censored p < Time (weeks) Thal + Dex median time to progression: 22.6 months Placebo + Dex median time to progression: 6.5 months Overall survival Thal + Dex Placebo + Dex Censored Time (weeks) Data from Rajkumar SV, et al. J Clin Oncol. 28;26:
17
18 Molecular Structure of Imids (Immunomodulatory drugs) 18
19 N Engl J Med 27;357:2123 MM9 Weber et al. NEJM 27
20 Lenalidomide + Dexamethasone in RRMM: Two Phase 3 Trials North American MM-9 (48 centres in the US, Canada; n = 353) 1 International MM-1 (5 centres in Europe, Australia, Israel; n = 351) 2 Mean follow-up length of MM-9: 17.6 months, MM-1: 16.4 months Len: 25 mg, Days 1 21 a Placebo: Days 1 21 a Dex: 4 mg, Days 1 4, 9 12, 17 2 for the first 4 cycles; 4 mg, Days 1 4 for subsequent cycles a Dex: 4 mg, Days 1 4, 9 12, 17 2 for the first 4 cycles; 4 mg, Days 1 4 for subsequent cycles a Continue until disease progression a Each course of treatment lasted 28 days. Len, Lenalidomide; Dex, dexamethasone 1. Weber DM, et al. N Engl J Med. 27;357: Dimopoulos M, et al. N Engl J Med. 27;357:
21 Patients, % Lenalidomide + Dexamethasone Significantly Prolonged TTP vs Placebo + Dexamethasone 1, Study Treatment n Median TTP p value MM-9 Len + Dex months 1 <.1 MM-9 Placebo + Dex months 1 MM-1 Len + Dex months 2 <.1 MM-1 Placebo + Dex months TTP, Months TTP with Lenalidomide + dexamethasone was significantly longer compared to placebo + dexamethasone in both trials (p <.1) 1. Weber DM, et al. N Engl J Med. 27;357: Dimopoulos M, et al. N Engl J Med. 27;357:
22 Patients, % Pooled MM-9/MM-1 Analysis: Lenalidomide + Dexamethasone Significantly Prolonged OS 1 8 Treatment Median OS p value Len + Dex 38. months.45 Placebo + Dex 31.6 months OS, Months Cross-over rate from Placebo + dexamethasone to Lenalidomidebased therapy was 47.6% Dimopoulos MA, et al. Leukemia. 29;23:
23 Safety Profile of Lenalidomide + Dexamethasone in RRMM AE, n (%) Lenalidomide + Dex Placebo + Dex Neutropenia 125 (35.4)** 12 (3.4) Thrombocytopenia 46 (13.)** 22 (6.3) Anaemia 38 (1.8)* 21 (6.) Pneumonia 32 (9.1) 19 (5.4) All thromboembolic events 56 (15.9)** 19 (5.4) Hyperglycaemia 27 (7.6) 27 (7.7) Fatigue 23 (6.5) 17 (4.9) Pooled analysis from MM-9 and MM-1: grade 3 AEs occurring in more than 5% of patients 1 *p <.1; ** p <.5. Dimopoulos MA, et al. Leukemia. 29;23:
24 Average Incidence (per 1 Person-Months) Hazard Rates of Haematologic AEs in Patients Continuously Treated With Lenalidomide + Dexamethasone 3 2 MM-9 and MM-1 Subgroup Analysis: 212 (of 353) Patients Who Achieved PR Neutropenia Thrombocytopenia Thrombotic events Time, Months Months N Neutropenia events Thrombocytopenia events Thrombotic events San Miguel JF, et al. Clin Lymphoma Myeloma Leuk. 211;11:38-43.
25 Incidence Rate (per 1 Person-Months) Incidence Rate (per 1 Person-Months) Neuropathy Risk Decreased During Lenalidomide + Dexamethasone Treatment Regardless of History of Neuropathy 25 MM-9 and MM-1 Subgroup Analysis With History of Neuropathy Without History of Neuropathy Severity Grade 1 Grade 2 Grade Severity Grade 1 Grade 2 Grade Time, Months Time, Months Delforge M, et al. Blood. 29;114:149. [abstract 3873].
26 Patients, % MM-9/1: Trend Toward Improved Median Survival With Continued Therapy After Achievement of Response 1 Patients discontinuing Len + Dex (n = 38) Patients continuing Len + Dex (n = 174) Median OS: 5.9 vs 35. months; p = OS, Months San Miguel JF, et al. Clin Lymphoma Myeloma Leuk. 211;11:34-43.
27 MM-9/1: Continuous Treatment With Lenalidomide and Dexamethasone Did Not Increase the Incidence of Gr 3 AEs Grade 3 Adverse Event, n (%) Patients (n = 174) 1 Total population (n= 351) 2 Neutropenia 72 (41) 125 (35) Thrombocytopenia 2 (12) 46 (13) Thrombotic events 19 (11) 56 (16) Hyperglycaemia 15 (9) 27 (8) Anaemia 13 (8) 38 (11) Pneumonia 13 (8) 32 (9) Hypokalaemia 1 (6) 2 (6) 112 patients (64%) required lenalidomide dose reductions/interruptions due to adverse events 42 patients (24%) received G-CSF support G-CSF, granulocyte-colony stimulating factor. 1. San Miguel JF, et al. Clin Lymphoma Myeloma Leuk. 211;11: Dimopoulos MA, et al. Leukemia. 29;23:
28 MM-15: Study Design * All patients received thromboprophylaxis during induction; thromboprophylaxis could be continued during maintenance at physician s discretion. Dex: dexamethasone; ISS: International Staging System; M: melphalan; MP: melphalan-prednisone; MPR: melphalan-prednisone-lenalidomide; MPR-R: melphalan-prednisone-lenalidomide followed by Lenalidomide maintenance; P: prednisone; PBO: placebo; R: Lenalidomide. Palumbo A. N Engl J Med. 212;366: MED/MM/REV/212.4/25
29 Patients (%) MM-15: Progression-Free Survival MPR-R significantly extended median PFS vs. MP and MPR 1 75 MPR-R MPR MP Median PFS 31 months 14 months 13 months 5 25 HR (P value) MPR-R vs. MPR:.49; P <.1 MPR-R vs. MP:.4; P < Time (months) HR: hazard ratio; MP: melphalan-prednisone; MPR: melphalan-prednisone-lenalidomide; MPR-R: melphalan-prednisone-lenalidomide followed by Lenalidomide maintenance; N/A: not applicable; PFS: progression-free survival. Palumbo A. N Engl J Med. 212;366: MED/MM/REV/212.4/25
30 Patients (%) MM-15: Overall Survival After a median follow-up of 3 months, the number of deaths was low (31% event rate) and comparable across all arms 3-year OS 1 75 MPR-R 7% MPR 62% MP 66% 5 25 HR (P value) MPR-R vs. MPR:.79; P =.25 MPR-R vs. MP:.95; P = Time (months) HR: hazard ratio; MP: melphalan-prednisone; MPR: melphalan-prednisone-lenalidomide; MPR-R: melphalan-prednisone-lenalidomide followed by Lenalidomide maintenance; N/A: not applicable; OS: overall survival. Palumbo A. N Engl J Med. 212;366: MED/MM/REV/212.4/25
31 FIRST Trial: Study Design RANDOMIZATION 1:1:1 PD or Unacceptable Toxicity PD, OS and Subsequent anti-mm Tx Screening Active Treatment + PFS Follow-up Phase LT Follow-Up Arm A Continuous Rd LEN + Lo-DEX Continuously LENALIDOMIDE 25mg D1-21/28 Lo-DEX 4mg D1,8,15 & 22/28 Arm B Rd18 LEN + Lo-DEX: 18 Cycles (72 wks) LENALIDOMIDE 25mg D1-21/28 Lo-DEX 4mg D1,8,15 & 22/28 Arm C MPT MEL + PRED + THAL 12 Cycles 1 (72 wks) MELPHALAN PREDNISONE THALIDOMIDE.25mg/kg D1-4/42 2mg/kg D1-4/42 2mg D1-42/42 Pts > 75 yrs: Lo-DEX 2 mg D1, 8, 15 & 22/28; THAL 2 (1 mg D1-42/42); MEL 2.2 mg/kg D1 4 Stratification: age, country and ISS stage ISS, International Staging System; LT, long-term; PD, progressive disease; OS, overall survival 1 Facon T, et al. Lancet 27;37:129-18; 2 Hulin C, et al. JCO. 29;27: Facon T, et al. Blood. 213;122:abstract 2.
32 FIRST Trial: Final Progression-free Survival Patients (%) Median PFS Rd (n=535) 25.5 mos Rd18 (n=541) MPT (n=547) Hazard ratio Rd vs. MPT:.72; P =.6 Rd vs. Rd18:.7; P =.1 Rd18 vs. MPT: 1.3; P = mos 21.2 mos 4 42% (Rd) 2 23% (Rd18) 23% (MPT) Time (months) Rd Rd MPT mos, months; MPT, melphalan, prednisolone, thalidomide; PFS, progression-free survival; Rd, lenalidomide plus low-dose dexamethasone. Facon T, et al. Blood. 213;122:abstract 2.
33 Patients (%) FIRST Trial: Overall Survival Interim Analysis deaths (35% of ITT) 4-year OS Rd (n= 535) 59.4% Rd18 (n= 541) 55.7% MPT (n= 547) 51.4% Hazard ratio Rd vs. MPT:.78; P =.168 Rd vs. Rd18:.9; P =.37 Rd18 vs. MPT:.88; P =.184 Rd Rd18 MPT Overall survival (months) Facon T, et al. Blood. 213;122:abstract 2.
34 IFM 25-2: Study Design and Endpoints Primary endpoint: PFS Secondary endpoints: ORR, EFS, OS Consolidation 2 28-day cycles Maintenance until progression N = 614 NDMM; < 65 years of age SD within 6 months of ASCT Stratified according to β 2 -M, del(13),* VGPR post-asct R 1:1 Lenalidomide 25 mg/day days 1-21 Lenalidomide 1-15 mg daily (n = 37) Placebo (n = 37) * As measured by FISH; Consolidation phase added at first protocol amendment (Sept 26); Thromboprophylaxis was not mandatory; 1 mg/day for the first 3 months, then increased to 15 mg/day if tolerated. ASCT: autologous stem cell transplant; β 2 -M: β 2 -microglobulin; del: deletion; EFS: event-free survival; FISH: fluorescence in situ hybridisation; IFM: Intergroupe Francophone du Myélome; NDMM: newly diagnosed multiple myeloma; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; R: randomisation; SD: stable disease; VGPR: very good partial response. Attal M. N Engl J Med. 212;366: MED/MM/REV/212.4/22
35 Patients (%) Patients (%) IFM 25-2: Progression-Free Survival Lenalidomide maintenance significantly prolonged median PFS vs. placebo 1 Cut-off: July 21 Cut-off: Oct 211 Median PFS HR (P value) LEN 41 months.5 (<.1) PBO 23 months N/A 1 4-year PFS HR (P value) LEN 43%.5 (<.1) PBO 22% N/A Follow-Up Follow-Up HR: hazard ratio; IFM: Intergroupe Francophone du Myélome; LEN: Lenalidomide; N/A; not applicable; PBO: placebo; PFS: progression-free survival. Attal M. N Engl J Med. 212;366: and Supplementary Appendix. MED/MM/REV/212.4/22
36 Patients (%) Poor Prognosis in Patients Ineligible for Novel Agents RRMM patients who are intolerant of or refractory to treatment with Lenalidomide, thalidomide, or bortezomib have a poor prognosis Median EFS: 5 months Median OS: 9 months 1 8 Survival Outcomes From Time Zero OS EFS Events/N 17/ /286 Median (range) in months 9 (7,11) 5 (4,6) Months From Time Zero Kumar SK. Leukemia. 212; 26:
37 Molecular Structure of Imids (Immunomodulatory drugs)
38 RANDOMIZATION 2:1 Dimopoulos MA, et al. Updated Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival in MM-3, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) vs High-Dose Dexamethasone (HiDEX) in Relapsed/Refractory Multiple Myeloma (RRMM). Oral presentation at: American Society of Hematology. 213; December 7-1; New Orleans, LA. MM-3 Design: POM + LoDEX vs. HiDEX 28-day cycles (n = 32) POM: 4 mg/day D LoDEX: 4 mg ( 75 yrs) 2 mg (> 75 yrs) D1, 8, 15, 22 PD a or Unacceptable AE Follow-Up for OS and SPM Until 5 Years Post Enrollment HiDEX: (n = 153) 4 mg ( 75 yrs) 2 mg (> 75 yrs) D1-4, 9-12, 17-2 PD a or Unacceptable AE Companion trial MM-3C POM 21/28 days Stratification Age ( 75 vs. > 75 yrs) Number of prior Tx ( 2 vs. > 2) Thromboprophylaxis was required for those receiving POM or at high risk for DVT Disease population (primary refractory vs. relapsed/refractory vs. intolerance/failure) a Progression of disease was independently adjudicated in real time.
39 MM-3: Overall Survival (ITT) Proportion of Patients 1. Median OS.8 POM + LoDEX (n = 32) HiDEX (n = 153) 13.1 mos 8.1 mos.6.4 HR =.72 P = OS (mos) 85 pts (56%) on the HiDEX arm received subsequent POM Dimopoulos MA, et al. Updated Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival in MM-3, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) vs High-Dose Dexamethasone (HiDEX) in Relapsed/Refractory Multiple Myeloma (RRMM). Oral presentation at: American Society of Hematology. 213; December 7-1; New Orleans, LA.
40 MM-3. OS Forest Plot of Subgroup Analyses Updated March Subgroup ITT Population HR (95%CI).74 ( ) POM + LoDEX* 145/32 HiDEX* 82/153 LEN and BORT Refractory.77 ( ) 113/225 62/113 LEN as Last Prior Tx.53 ( ) 41/85 29/49 BORT as Last Prior Tx.87 ( ) 56/132 3/ Favors POM + LoDEX Favors HiDEX * Number of events/number of pts San Miguel JF, et al. ASCO 213 [abstract 851].
41 MM-3 Phase 3: Safety Event Grade 3/4 haematological AEs, % POM + LoDEX (N = 3) HiDEX (N = 15) Neutropenia Febrile neutropenia 9 Anaemia Thrombocytopenia Grade 3/4 non-haematological AEs, % Infection 3 24 Pneumonia 13 8 Bone pain 7 5 Fatigue 5 6 Asthenia 4 6 Glucose intolerance 3 7 Grade 3/4 AEs of interest, % DVT/PE 1 Peripheral neuropathy a 1 1 Discontinuation due to AEs, % 9 1
42 Survival distribution function estimate Pomalidomide IFM 29-2: superior Comparison to any between approach TTP on-protocol & TTP post on Bortezomib last prior line and (ITT Lenalidomide N = 84) TTP last prior line TTP pomalidomide TTP last prior line (IRC responders) TTP pomalidomide (IRC responders) IRC = Independent review committee; ITT = intent-to-treat; TTP = time-to-progression Time from first intake (weeks) 2
43 IMiDs A new backbone of therapy: Lenalidomide Proteasome inhibitors Rd + carfilzomib in RRMM, phase 3 (US/EU), phase 1/2 (US) Rd + MLN978 in RRMM: phase 3 (USA, Canada, EU) Rd + MLN978 in NDMM: phase 3 (USA, Canada, France, Belgium, Japan) HDAC inhibitors Rd + vorinostat in RRMM: multiple phase 1/2 (US, EU), 1 phase 3 (USA) Rd + panobinostat in RRMM: 2 phase1/2 (USA, Australia, EU) Rd + ACY-1215 in RRMM: phase 1 (USA) Monoclonal antibodies Rd + elotuzumab in RRMM: multiple phase 1/2 (EU, USA, Japan), 1 phase 3 (ELOQUENT-2) Rd + elotuzumab in NDMM: phase 3 (ELOQUENT-1) Rd + daratumumab in RRMM: 1 phase 3 Rd + SAR65984 in RRMM: phase 1 (USA) Rd + IPH211 in RRMM: phase 1 (USA)
44 IMiDs in numbers Trials (as per clinicaltrials.gov, dd 12 May 214) Open Total Thalidomide Lenalidomide Pomalidomide Publications (as per pubmed, dd 12 May 214) total (no date filter) Thalidomide Lenalidomide Pomalidomide
45 Model of the disease course in Pattern of disease multiple in myeloma multiple myeloma M protein (g/dl) 1 Asymptomatic Symptomatic Active myeloma 5 2 MGUS or smouldering myeloma Plateau remission Relapse Refractory relapse Time Durie BGM Concise review of the disease and treatment options. Multiple myeloma. North Hollywood, CA: International Myeloma Foundation. Available from: Eng_l2.pdf. Accessed November 212.
46 M-protein (g/l) Proposed Updated Model Multiple myeloma: changing the paradigm in the RRMM setting 1 Active MM Lenalidomide FIRST RELAPSE SECOND RELAPSE Pomalidomide THIRD RELAPSE REFRACTORY RELAPSE 5 2 MGUS or SMM Plateau remission First-line therapy Second-line therapy Third-line therapy ACTIVE MYELOMA
47 Never give up! We will make it Thank you for your attention
Management of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationMultiple Myeloma: Approach to the Elderly
Multiple Myeloma: Approach to the Elderly Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON PMH Myeloma Day May 12, 2017 Peter Anglin MD Disclosures Speakers Bureau Advisory Boards
More informationPomalidomide: a new hope for relapsed and refractory multiple myeloma
4 Pomalidomide: a new hope for relapsed and refractory multiple myeloma C. Doyen, MD 1 Relapsed and refractory multiple myeloma patients have a particularly poor prognosis and the development of new drugs
More informationHorizon Scanning Centre November Pomalidomide for multiple myeloma third line SUMMARY NIHR HSC ID: 4436
Horizon Scanning Centre November 2012 Pomalidomide for multiple myeloma third line SUMMARY NIHR HSC ID: 4436 This briefing is based on information available at the time of research and a limited literature
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationDevelopments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D.
Developments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D. Kraft Family Professor of Medicine Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer
More informationElotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)
A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationNew Drugs on the Horizon Providing Hope for Multiple Myeloma Patients Kenneth C. Anderson, M.D.
New Drugs on the Horizon Providing Hope for Multiple Myeloma Patients Kenneth C. Anderson, M.D. Kraft Family Professor of Medicine Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More informationCurrent treatment options for relapsed/refractory multiple myeloma in practice
Current treatment options for relapsed/refractory multiple myeloma in practice Professor Marίa-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain Please note that discussion throughout
More informationPhase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma Jatin J Shah, MD 1, Robert Z. Orlowski, MD, PhD 1, Raymond Alexanian, MD 1, Michael
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationConflict of Interest Disclosure Form
Conflict of Interest Disclosure Form NAME : Niels van de Donk MD-PhD AFFILIATION: University of California San Francisco. In accordance with the rules of the Health Care Inspectorate (IGZ), speakers are
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationOvercoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma
Overcoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma George Somlo M.D. City of Hope Comprehensive Cancer Center The Cause 1 Myeloma: Clinical Features Bone
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationPlasma cells in bone marrow. Treatment of Multiple Myeloma Novel Approaches. Approach to Progressive MM. Approach to Initial Therapy
Treatment of Multiple Myeloma ovel Approaches Plasma cells in bone marrow Donna E. Reece, M.D. Princess Margaret Hospital Toronto, 21 ctober 25 Adhesion Molecules and Growth Factors in Multiple Myeloma
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationInternational Myeloma Foundation Patient and Family Seminar
International Myeloma Foundation Patient and Family Seminar Vienna, Austria May 6 th, 2006 New Development in Diagnosis & Treatments Brian G.M. Durie, M.D., Chairman International Myeloma Foundation What
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationIs sustained triplet therapy the new standard of care in relapsed/refractory multiple myeloma?
Takeda Oncology-sponsored satellite symposium at the British Society for Haematology (BSH) 57 th Annual Scientific Meeting Is sustained triplet therapy the new standard of care in relapsed/refractory multiple
More informationScottish Medicines Consortium
Scottish Medicines Consortium lenalidomide, 5mg,10mg,15mg and 25mg capsules (Revlimid) No. (441/08) Celgene Europe Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment of
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationwhich to base economic assessment of the products available to treat this hematologic
special feature Measuring Value of Multiple Myeloma Therapies by Gary M. Owens, MD, Gary Owens Associates As recent therapies for multiple myeloma (MM) have provided significant improvements in the prognosis
More information